

News Release

Lonza Publishes Invitation to the 2018 Annual General Meeting and Annual Report 2017

- **Annual General Meeting to take place on 4 May 2018 in Basel**
- **Albert M. Baehny proposed as new Chairperson of the Board of Directors**
- **Angelica Kohlmann and Olivier Verscheure proposed as new members of the Board of Directors**
- **Stable dividend of CHF 2.75 per share proposed**
- **New online Annual Report published**

Basel, Switzerland, 22 March 2018 – Lonza today announced that it has published its Online Annual Report 2017 and its invitation to the Annual General Meeting 2018, which will take place on **Friday, 4 May 2018, at 10:00 a.m. CEST**, at the Congress Center Messe Basel, Messeplatz 21, 4058 Basel, Switzerland.

Annual General Meeting

The Annual General Meeting (AGM) invitation can be accessed on Lonza's website by clicking on "Annual General Meeting" on the following webpage: www.lonza.com/about-lonza/investor-relations/investor-information

The Board of Directors proposes the election of Albert M. Baehny, currently Vice Chairperson of the Board, as Chairperson of the Board of Directors. Rolf Soiron (Chairperson), as announced a year ago, and Jean-Daniel Gerber (Chair of the Nominations and Compensation Committee) have decided not to stand for re-election at the AGM 2018. The Board would like to thank them for their contributions during their years of service.

The Board of Directors is proposing to Lonza's AGM the election of two new Board members, Angelica Kohlmann and Olivier Verscheure.

Angelica Kohlmann is a German-Brazilian entrepreneur, investor and medical doctor. Her broad experience of more

than 25 years in the fields of pharmaceuticals and biotech, tech and big data, management and international business – including the launch of several companies – will be valuable to Lonza.

Angelica Kohlmann is Chairperson and CEO of the family-holding Kohlmann & Co AG, serves on several boards and is Chairman of the Advisory Board of the Global Peter Drucker Forum, Vienna (AT). She holds an MD and a Doctoral degree from Hamburg University (DE).

In May 2016 Olivier Verscheure became the Executive Director of the Swiss Data Science Center, a national R&D center hosted by both the Swiss Federal Institute of Technology (EPFL) in Lausanne (CH) and the Eidgenössische Technische Hochschule (ETH) in Zurich (CH).

Together with his prior professional career at the IBM T.J. Watson Research Center in New York and the IBM Research Lab in Ireland, he brings to Lonza extensive insights into the rapidly changing digital world and its latest developments. Olivier Verscheure received his Ph.D. degree in computer science from EPFL in 1999.

The Board is further proposing to the AGM the re-election of all other Board members. Further motions include the election of the Nominations and Compensation Committee and the approval of the compensation of the Board of Directors and the Executive Committee.

Lonza's Board of Directors is proposing a stable dividend for shareholders of CHF 2.75 per share for 2017, despite a 40.7% increase in share capital. Subject to approval at the Annual General Meeting, the dividend of CHF 2.75 per share for 2017 will be paid out of the reserve capital contribution and will be free from Swiss withholding tax.

All details on the motions can be found in the invitation to the Annual General Meeting 2018.

Online Annual Report

Last year Lonza switched from a printed to an Online Annual Report. The online report and the downloadable PDF can be accessed through the following website:
<http://annualreport.lonza.com/2017>

The online report is separated into five sections: Company Overview, Segments, Financial Overview including financial statements and notes, Remuneration Report and Corporate Governance Report.

By eliminating the formal printing of thousands of reports, Lonza aims to reduce its impact on the environment. The switch to online and PDF versions also saves money required for printing and mailing.

About Lonza

Lonza is one of the world's leading and most-trusted suppliers to the pharmaceutical, biotech and specialty ingredients markets. As an integrated solutions provider, Lonza is boosting its value creation along and beyond the healthcare continuum with a strong focus on patient healthcare, consumer preventive healthcare and consumer's healthy environment.

Lonza harnesses science and technology to create products that support safer and healthier living and that enhance the overall quality of life. With the recent Capsugel acquisition, Lonza now offers products and services from the custom development and manufacturing of active pharmaceutical ingredients to innovative dosage forms for the pharma and consumer health and nutrition industries.

Benefiting from its regulatory expertise, Lonza is able to transfer its know-how from pharma to hygiene and fast-moving consumer goods all the way to coatings and composites and the preservation and protection of agricultural goods and other natural resources.

Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 100 sites and offices and approximately 14,500 full-time employees worldwide. The company generated sales of CHF 5.1 billion in 2017 with a CORE EBITDA of CHF 1.3 billion. Further information can be found at www.lonza.com.

Contact Details**Dirk Oehlers**, Head Investor Relations

Lonza Group Ltd
Tel +41 61 316 8540
dirk.oehlers@lonza.com

Dominik Werner, Head Corporate Communications

Lonza Group Ltd
Tel +41 61 316 8798
dominik.werner@lonza.com

Dr. Kristin Köhler, Senior Manager Investor Relations

Lonza Group Ltd
Tel +41 61 316 8782
kristin.koehler@lonza.com

Constance Ward, Head External Communications

Lonza Group Ltd
Tel +41 61 316 8840
constance.ward@lonza.com

Additional Information and Disclaimer

Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited ("SGX-ST"). Lonza Group Ltd is not subject to the SGX-ST's continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.

Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.